Skip to main content

Table 2 Number of participants (target, enrolled) by cohort, sex (UCPPS: duration of symptoms), and number of participants with biospecimens by type, MRI scans completed and PPT data collected at baseline visit

From: The MAPP research network: design, patient characterization and operations

Cohorts No. of participants by cohort No. of participants with biospecimens No. of participants with MRI scans No. of Participants with Pain Pressure Threshold (PPT) measures
Target size Actual enrolled Cheek swab Biomarker samples Infectious etiology urine samples At baseline During follow-up
Plasma Urine VB1 VB2 VB3
UCPPS (Duration of symptoms)
Male < 2 Yrs 95 90 90 90 90 90 90 39 13 19 20
Male ≥ Yrs 95 101 100 100 101 100 100 42 22 12 20
Female < 2 Yrs 95 89 89 86 89 89 88 0 22 20 19
Female ≥2 Yrs 95 144 144 142 144 142 139 0 41 11 23
Total 380 424 423 418 424 421 417 81 98 62 82
Healthy controls
Male 190 182 182 177 181 176 174 64 38 40 0
Female 190 233 233 228 232 232 227 0 79 60 0
Total 380 415 415 405 413 408 401 64 117 100 0
Positive controls
Male 95 44 44 43 43 43 43 10 17 8 0
Female 95 156 156 154 154 154 152 0 47 27 0
Total 190 200 200 197 197 197 195 10 64 35 0
Overall total 950 1,039 1,038 1,020 1,034 1,026 1,013 155 279 197 82
\